Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_assertion type Assertion NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_head.
- NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_assertion wasGeneratedBy ECO_0000203 NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_provenance.
- NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_assertion wasDerivedFrom befree-20140225 NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_provenance.
- NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_assertion SIO_000772 23468880 NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_provenance.
- NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_assertion evidence source_evidence_literature NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_provenance.
- NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_assertion description "[Additionally, results from a Phase I trial of MEHD7495A, a dual-action antibody that blocks ligand binding to EGFR and HER3, suggest that high-level HRG expression was associated with clinical response in SCCHN patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_provenance.